Chronic lymphocytic leukemia-- or CLL-- is a type of cancer that happens in your blood and bone marrow, the spongy tissue inside your bones. While the exact cause isn't known, doctors do know that ...

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...

Although a relatively rare phenomenon, lymphocytic hypophysitis can represent a difficult diagnostic and therapeutic challenge. This condition was initially thought to be an autoimmune phenomenon ...

CART, a next-gen CAR-T therapy for improved targeting and functionality to address this. “ALA-CART improves the ability of ...

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

Research into immunotherapy against cancer typically focuses on better recognition of cancer cells by the body's own immune ...

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

SUV remains the most widely used PET parameter to evaluate NHLs because it is directly associated with lymphoma aggressiveness.

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...

Maple Hill Elementary School second-grader Amare Murphy was diagnosed with T Cell All Leukemia or acute lymphocytic leukemia ...

Lymphocytic colitis was first described in 1989 by Lazenby et al., at which time it was thought to be uncommon.Epidemiological studies have now revealed that lymphocytic colitis is a relatively ...

The following is a summary of "BCL-2 dependence is a favorable predictive marker of response to therapy for chronic ...